Literature DB >> 25487048

Prostate cancer: Bicalutamide dose increase in castration-resistant disease.

Fernand Labrie1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25487048     DOI： 10.1038/nrurol.2014.334

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

Review 1.  The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE.

Authors:  Hideyuki Akaza; Shiro Hinotsu; Michiyuki Usami; Osamu Ogawa; Susumu Kagawa; Tadaichi Kitamura; Taiji Tsukamoto; Seiji Naito; Yoshihiko Hirao; Masaru Murai; Hidetoshi Yamanaka; Mikio Namiki
Journal:  J Urol       Date:  2006-12       Impact factor: 7.450

2.  Estimated potency of Casodex: a problematic design.

Authors:  F Labrie; J Simard; S M Singh; B Candas
Journal:  Urology       Date:  1997-08       Impact factor: 2.649

3.  Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  2000-04-29       Impact factor: 79.321

Review 4.  Clinical progress with a new antiandrogen, Casodex (bicalutamide).

Authors:  G R Blackledge
Journal:  Eur Urol       Date:  1996       Impact factor: 20.096

5.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

6.  An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study.

Authors:  L Klotz; D Drachenberg; R Singal; A Aprikian; Y Fradet; M Kebabdjian; M Zarenda; J Chin
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-09-02       Impact factor: 5.554

7.  A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer.

Authors:  G T Bales; G W Chodak
Journal:  Urology       Date:  1996-01       Impact factor: 2.649

8.  Benefits of combination therapy with flutamide in patients relapsing after castration.

Authors:  F Labrie; A Dupont; M Giguere; J P Borsanyi; Y Lacourciere; G Monfette; J Emond; N Bergeron
Journal:  Br J Urol       Date:  1988-04

9.  New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.

Authors:  F Labrie; A Dupont; A Belanger; L Cusan; Y Lacourciere; G Monfette; J G Laberge; J P Emond; A T Fazekas; J P Raynaud; J M Husson
Journal:  Clin Invest Med       Date:  1982       Impact factor: 0.825

10.  A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.

Authors:  P Schellhammer; R Sharifi; N Block; M Soloway; P Venner; A L Patterson; M Sarosdy; N Vogelzang; J Jones; G Kolvenbag
Journal:  Urology       Date:  1995-05       Impact factor: 2.649
  10 in total
  1 in total

1.  Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer.

Authors:  Su-bo Qian; Hai-bo Shen; Qi-feng Cao; Lin Zhang; Yi-fan Chen; Jun Qi
Journal:  Int Urol Nephrol       Date:  2015-02-10       Impact factor: 2.370
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.